• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Exscientia Plc (Amendment)

    4/11/23 5:00:57 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXAI alert in real time by email
    SC 13D/A 1 d498633dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Exscientia plc

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    30223G102

    (CUSIP Number)

    SB Global Advisers Limited

    Attn: Stephen Lam

    69 Grosvenor St

    Mayfair, London W1K 3JP

    +44 0207 629 0431

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 1, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 30223G102    13D    Page 1 of 11 pages

     

      1    

      Names of Reporting Persons

     

      SVF II Excel (DE) LLC

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      18,977,218

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      18,977,218

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      18,977,218

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      15.4%

    14  

      Type of Reporting Person

     

      OO (Limited Liability Company)

     


    CUSIP No. 30223G102    13D    Page 2 of 11 pages

     

      1    

      Names of Reporting Persons

     

      SVF II Investment Holdings (Subco) LLC

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      18,977,218

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      18,977,218

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      18,977,218

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      15.4%

    14  

      Type of Reporting Person

     

      OO (Limited Liability Company)

     


    CUSIP No. 30223G102    13D    Page 3 of 11 pages

     

      1    

      Names of Reporting Persons

     

      SB Global Advisers Limited

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      England and Wales

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      18,977,218

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      18,977,218

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      18,977,218

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      15.4%

    14  

      Type of Reporting Person

     

      CO

     


    CUSIP No. 30223G102    13D    Page 4 of 11 pages

     

      1    

      Names of Reporting Persons

     

      SoftBank Group Corp.

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Japan

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      18,977,218

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      18,977,218

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      18,977,218

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      15.4%

    14  

      Type of Reporting Person

     

      CO

     


    CUSIP No. 30223G102    13D    Page 5 of 11 pages

     

    EXPLANATORY NOTE

    This Amendment No. 1 amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “SEC”) on October 15, 2021 (as amended to date, the “Schedule 13D”) with respect the ordinary shares, nominal value £0.0005 per share (the “Ordinary Shares”), of Exscientia plc, a corporation incorporated in England and Wales (the “Issuer”). Capitalized terms used herein and not otherwise defined shall have the same meanings ascribed to them in the Schedule 13D.

     

    Item 2.

    Identity and Background.

    Item 2 of the Schedule 13D is amended and restated in its entirety as follows:

    The Schedule 13D is being filed by the following entities (each a “Reporting Person” and collectively, the “Reporting Persons”):

    SVF II Excel (DE) LLC

    SVF II Investment Holdings (Subco) LLC

    SB Global Advisers Limited (“SBGA”)

    SoftBank Group Corp. (“SoftBank”)

    Each of SVF II Excel (DE) LLC and SVF II Investment Holdings (Subco) LLC is organized under the laws of the State of Delaware. SBGA is organized under the laws of England and Wales. SoftBank is organized under the laws of Japan.

    The business address of each of SVF II Excel (DE) LLC and SVF II Investment Holdings (Subco) LLC is 251 Little Falls Drive, Wilmington, DE 19808. The business address of SBGA is 69 Grosvenor Street, Mayfair, London W1K 3JP, England, United Kingdom. The business address of SoftBank is 1-7-1, Kaigan, Minato-ku Tokyo 105-7537 Japan. Each of the Reporting Persons is principally engaged in the business of investments in securities.

    The directors of SBGA and the directors and executive officers of SoftBank are set forth in Schedule A to this Schedule 13D (collectively, the “Related Persons”).

    During the last five years, none of the Reporting Persons nor any Related Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 4.

    Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:


    CUSIP No. 30223G102    13D    Page 6 of 11 pages

     

    Internal Restructuring

    As a result of an internal restructuring on April 1, 2023, SoftBank may be deemed to share beneficial ownership of the securities reported herein.

     

    Item 5.

    Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is amended and restated in its entirety as follows:

    (a) – (b)

    The following sets forth, as of the date of this Schedule 13D, the aggregate number of Ordinary Shares and percentage of Ordinary Shares beneficially owned by each of the Reporting Persons, as well as the number of Ordinary Shares as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 122,963,545 Ordinary Shares outstanding as of December 31, 2022, as disclosed in the Issuer’s Annual Report on Form 20-F filed with the SEC on March 23, 2023:

     

    Reporting Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole power
    to vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole power
    to dispose
    or to direct
    the
    disposition
         Shared
    power to
    dispose or to
    direct the
    disposition
     

    SVF II Excel (DE) LLC

         18,977,218        15.4 %      0        18,977,218        0        18,977,218  

    SVF II Investment Holdings (Subco) LLC

         18,977,218        15.4 %      0        18,977,218        0        18,977,218  

    SB Global Advisers Limited

         18,977,218        15.4 %      0        18,977,218        0        18,977,218  

    SoftBank Group Corp.

         18,977,218        15.4 %      0        18,977,218        0        18,977,218  

    SVF II Excel (DE) LLC is the record holder of 13,295,400 Ordinary Shares and 5,681,818 Ordinary Shares represented by 5,681,818 ADS.

    SoftBank, which is a publicly traded company listed on the Tokyo Stock Exchange, is the sole shareholder of SBGA, which has been appointed as manager and is exclusively responsible for making all final decisions related to the acquisition, structuring, financing and disposal of SVF II Investment Holdings (Subco) LLC’s investments, including as held by SVF II Excel (DE) LLC. SVF II Investment Holdings (Subco) LLC is the sole member of SVF II Excel (DE) LLC. As a result of these relationships, each of the foregoing entities may be deemed to share beneficial ownership of the securities reported herein.

    (c) During the past 60 days, none of the Reporting Persons or the Related Persons have effected any transactions in the Ordinary Shares.

    (d) None.


    CUSIP No. 30223G102    13D    Page 7 of 11 pages

     

    (e)

    Not applicable.

     

    Item 7.

    Materials to be Filed as Exhibits

    Item 7 of the Schedule 13D is amended and supplemented as follows:

     

    Exhibit
    Number
      

    Description

    1    Joint Filing Agreement.


    CUSIP No. 30223G102    13D    Page 8 of 11 pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: April 11, 2023

     

    SVF II Excel (DE) LLC

    By:

     

    /s/ Jonathan Duckles

    Name:

     

    Jonathan Duckles

    Title:

     

    Director

    SVF II Investment Holdings (Subco) LLC

    By:

     

    /s/ Jonathan Duckles

    Name:

     

    Jonathan Duckles

    Title:

     

    Director

    SB Global Advisers Limited

    By:

     

    /s/ Alex Clavel

    Name:

     

    Alex Clavel

    Title:

     

    Director

    SoftBank Group Corp.

    By:

     

    /s/ Yuko Yamamoto

    Name:

     

    Yuko Yamamoto

    Title:

     

    Head of Corporate Legal Department


    CUSIP No. 30223G102    13D    Page 9 of 11 pages

     

    Schedule A

    Set forth below is a list of each executive officer and director of SB Global Advisers Limited and SoftBank Group Corp., including the name, citizenship, business address and present principal occupation or employment (and the name and address of any corporation or organization in which such employment is conducted) of each individual.

    SB GLOBAL ADVISERS LIMITED

     

    Name and Citizenship

      

    Present Principal Occupation

    (principal business of employer)

      

    Business Address

    Alex Clavel, a citizen of the United States    Board Director and Executive Committee member of SB Global Advisers Limited and Board Director of SoftBank Group Capital Limited and Board Director, Chief Executive Officer and President of SB Group US, Inc.   

    69 Grosvenor Street, London,

    United Kingdom W1K 3JP

     

    430 Park Avenue, 16th Floor

    New York, NY 10022, United States

    Yoshimitsu Goto, a citizen of Japan    Board Director of SB Global Advisers Limited and Board Director, Corporate Officer, Senior Vice President, CFO, CISO & CSusO of SoftBank Group Corp.   

    69 Grosvenor Street, London,

    United Kingdom W1K 3JP

     

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Navneet Govil, a citizen of the United States    Board Director and Executive Committee Member of SB Global Advisers Limited, Board Director of SB Global Advisers (US) Inc., and CFO of the SoftBank Investment Advisers Group   

    69 Grosvenor Street, London,

    United Kingdom W1K 3JP

     

    1 Circle Star Way, San Carlos, California 94070, United States

    Timothy A. Mackey, a citizen of New Zealand    Board Director of SB Global Advisers Limited and Corporate Officer, CLO & GCO of SoftBank Group Corp.   

    69 Grosvenor Street, London,

    United Kingdom W1K 3JP

     

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Gyu Hak Moon, a citizen of South Korea    Board Director and Executive Committee member of SB Global Advisers Limited   

    69 Grosvenor Street, London,

    United Kingdom W1K 3JP

     

    138 Market Street, #27-01A, CapitaGreen Building, Singapore 048946


    CUSIP No. 30223G102    13D    Page 10 of 11 pages

     

    SOFTBANK GROUP CORP.

     

    Name and Citizenship

      

    Present Principal Occupation

    (principal business of employer)

      

    Business Address

    Masayoshi Son*, a citizen of Japan    Representative Director, Corporate Officer, Chairman & CEO of SoftBank Group Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Yoshimitsu Goto*, a citizen of Japan    Board Director, Corporate Officer, Senior Vice President, CFO, CISO & CSusO of SoftBank Group Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Ken Miyauchi*, a citizen of Japan    Board Director of SoftBank Group Corp.; Director & Chairman, SoftBank Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Kentaro Kawabe*, a citizen of Japan    Board Director of SoftBank Group Corp.; Chairperson and Representative Director, Z Holdings Corporation; Executive Director, ZOZO, Inc.; Board Director, SoftBank Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Keiko Erikawa*, a citizen of Japan    External Board Director, Independent Officer of SoftBank Group Corp.; Chairman Emeritus (Director), KOEI TECMO GAMES CO., LTD; Board Director, KOEI TECMO EUROPE LIMITED; Chairman (Representative Director), KOEI TECMO HOLDINGS CO., LTD.; Director, Foundation for the Fusion Of Science and Technology   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    David Chao*, a citizen of Japan    External Board Director, Independent Officer of SoftBank Group Corp.; Co-Founder and General Partner, DCM Ventures   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Masami Iijima*, a citizen of Japan    External Board Director, Independent Officer of SoftBank Group Corp.; Director, Ricoh Company, Ltd.; Director, Isetan Mitsukoshi Holdings Ltd.; Counsellor, Bank of Japan; Counselor, MITSUI & CO., LTD.; Director, Takeda Pharmaceutical Company Limited   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

     

    MITSUI & CO., LTD.

    2-1, Otemachi 1-chome, Chiyoda-ku,

    Tokyo 100-8631

    Japan

    Yutaka Matsuo*, a citizen of Japan    External Board Director, Independent Officer of SoftBank Group Corp. and Professor, Graduate School of Engineering at the University of Tokyo   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Kenneth A. Siegel*, a citizen of the United States of America    External Board Director of SoftBank Group Corp.; Board Director, Member of Executive Committee, Morrison & Foerster LLP   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

     

    Shin-Marunouchi Building, 29th Floor

    5-1, Marunouchi 1-Chome

    Chiyoda-ku, Tokyo, Japan 100-6529


    CUSIP No. 30223G102    13D    Page 11 of 11 pages

     

    Soichiro Uno**, a citizen of Japan    External Audit & Supervisory Board Member of SoftBank Group Corp.; Partner at Nagashima Ohno & Tsunematsu; Director at Dream Incubator Inc.; and Director at TERUMO CORPORATION   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Yuji Nakata**, a citizen of Japan    External Audit & Supervisory Board Member of SoftBank Group Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Maurice Atsushi Toyama**, a citizen of the United States of America    External Audit & Supervisory Board Member of SoftBank Group Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Keiichi Otsuka**, a citizen of Japan    External Audit & Supervisory Board Member of SoftBank Group Corp.; Director, Shizuoka Bank (Europe) S.A.; Representative of Otsuka CPA Office; Audit & Supervisory Board Member, TBK Co., Ltd.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Kazuko Kimiwada, a citizen of Japan    Corporate Officer, Senior Vice President of SoftBank Group Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Timothy A. Mackey, a citizen of New Zealand    Corporate Officer, CLO & GCO of SoftBank Group Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

    Seiichi Morooka, a citizen of Japan    Corporate Officer of SoftBank Group Corp.   

    SoftBank Group Corp.

    1-7-1 Kaigan,

    Minato-ku, Tokyo 105-7537

    Japan

     

    *

    Director

    **

    Corporate Auditor

     

    Get the next $EXAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAI

    DatePrice TargetRatingAnalyst
    7/9/2024Buy
    TD Cowen
    1/5/2024$11.00 → $9.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $EXAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

      Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, wi

      11/20/24 7:00:00 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion and Exscientia Shareholders Approve the Proposed Combination

      Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.  The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET /  5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of

      11/13/24 9:08:19 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

      Both programmes demonstrate Exscientia's ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages Exscientia plc (NASDAQ:EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds

      10/16/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Financials

    Live finance-specific insights

    See more
    • Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

      Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R

      7/18/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Business Update for First Quarter 2024

      Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and streamlining operations to realise annualised savings of $40 million Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscient

      5/21/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

      Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 (800) 358 0970 (U.K.), +1 (646) 960 0857 (International)

      5/14/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

      Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

      8/8/24 7:39:25 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

      — AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia's internal oncology pipeline — Exscientia plc (NASDAQ:EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. Appointed to Chief Technology Officer, John P. Overington, Ph.D.,

      6/6/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parker Moss to Join Exscientia as EVP, Corporate Development

      Renowned technology champion to strengthen company's development of precision medicine and clinical innovation platforms Exscientia plc (NASDAQ:EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company's precision medicine, clinical and tech innovation platforms, with a particular focus on oncology. Reporting to CEO Andrew Hopkins, he will help the company's Executive Leadership Team to identify and shape new business opportuni

      10/17/23 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Exscientia Plc

      15-12G - Exscientia plc (0001865408) (Filer)

      12/2/24 8:39:14 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Exscientia Plc

      S-8 POS - Exscientia plc (0001865408) (Filer)

      11/20/24 10:01:22 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Exscientia Plc

      S-8 POS - Exscientia plc (0001865408) (Filer)

      11/20/24 9:53:01 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Exscientia plc

      TD Cowen initiated coverage of Exscientia plc with a rating of Buy

      7/9/24 7:31:11 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia plc downgraded by BofA Securities with a new price target

      BofA Securities downgraded Exscientia plc from Buy to Neutral and set a new price target of $9.00 from $11.00 previously

      1/5/24 7:41:29 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exscientia Plc

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      11/22/24 9:11:55 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Exscientia Plc

      SC 13D/A - Exscientia plc (0001865408) (Subject)

      11/22/24 8:00:16 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Exscientia Plc (Amendment)

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      2/12/24 11:05:40 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care